| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/18/2004 | EP1389137A2 Compositions for protein delivery via the pulmonary route |
| 02/18/2004 | EP1389132A2 Peg-conjugates of hgt-nk4 |
| 02/18/2004 | EP1389128A2 Method for inhibiting atherosclerotic plaque formation |
| 02/18/2004 | EP1389125A1 Cross-linked gelatin composition comprising a wetting agent |
| 02/18/2004 | EP1389118A1 Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle |
| 02/18/2004 | EP1389115A2 As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation |
| 02/18/2004 | EP1389106A1 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications |
| 02/18/2004 | EP1389101A1 Toluene sulfonamide-containing anti-tumor composition and method of use thereof |
| 02/18/2004 | EP1389099A1 Delivery of beta-blockers through an inhalation route |
| 02/18/2004 | EP1389098A1 Delivery of antipsychotics through an inhalation route |
| 02/18/2004 | EP1389097A1 Delivery of compounds for the treatment of parkinsons through an inhalation route |
| 02/18/2004 | EP1389096A1 Delivery of opioids through an inhalation route |
| 02/18/2004 | EP1389095A1 Delivery of antidepressants through an inhalation route |
| 02/18/2004 | EP1389094A1 Delivery of sedative-hypnotics trough an inhalation route |
| 02/18/2004 | EP1389093A2 Pharmaceutical formulation |
| 02/18/2004 | EP1389092A1 Abuse-resistant opioid dosage form |
| 02/18/2004 | EP1389091A1 Granular preparations of gaboxadol |
| 02/18/2004 | EP1389090A2 Diagnostic imaging compositions, their methods of synthesis and use |
| 02/18/2004 | EP1389089A2 Method and composition for solubilising a biologically active compound with low water solubility |
| 02/18/2004 | EP1267932B1 Anti-infective active substance combinations and the use thereof for the topical treatment of fungus diseases of toe and finger nails |
| 02/18/2004 | EP1237408B1 Pour-on formulations |
| 02/18/2004 | EP1194136B1 Non-solid composition for local application comprising glycerol and alchemilla vulgaris extract |
| 02/18/2004 | EP1178736B1 A composition containing carvacrol and thymol for use as a bactericide |
| 02/18/2004 | EP1137407B1 Ophthalmic formulation comprising a beta blocker and carbopol |
| 02/18/2004 | EP1131089B1 Stable aqueous insulin preparations without phenol and cresol |
| 02/18/2004 | EP1075287B1 Positron emission tomography using gallium-68 chelates |
| 02/18/2004 | EP1019090B1 Polymeric derivatives of camptothecins |
| 02/18/2004 | EP0994696B1 Controlled release pharmaceutical preparation with ace inhibitor as active agent |
| 02/18/2004 | EP0967995B1 Composition comprising immunoglobulin |
| 02/18/2004 | EP0948337B1 Treatment of hemoglobin containing erythrocytes with nitric oxide |
| 02/18/2004 | EP0863765B1 Pharmaceutical compositions of cyclosporine with a polyethoxylated saturated hydroxy-fatty acid |
| 02/18/2004 | EP0734264B1 Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| 02/18/2004 | EP0728012B1 NOVEL GnRH ANALOGUES WITH ANTITUMOUR EFFECTS AND PHARMACEUTICAL COMPOSITIONS THEREOF |
| 02/18/2004 | EP0691852B1 Valproic acid covalently bonded to a lysophospholipid |
| 02/18/2004 | CN1476335A Freeze-dried pantoprazole preparation and pantoprazole injection |
| 02/18/2004 | CN1476330A Polymeric micelle containing cisplatin enclosed therein and use thereof |
| 02/18/2004 | CN1476327A Water-soluble liquid internal medicine |
| 02/18/2004 | CN1476325A Active agent delivery systems and methods for protecting and administering active agents |
| 02/18/2004 | CN1476318A O/W emulsion composition and method of preparing same |
| 02/18/2004 | CN1475209A Slow-released agent form of sertraline |
| 02/18/2004 | CN1475208A Slow-released agent form of sertraline |
| 02/18/2004 | CN1475207A Solid oral dosage mode containing walshaden and hydrochloric thizaine |
| 02/18/2004 | CN1475204A Medicinal Composition, dry powder vapor, nebula, nebula auxiliary preparation for use through mouth and nose and its preparation method |
| 02/18/2004 | CN1138809C 聚酯 Polyester |
| 02/18/2004 | CN1138591C Coated particles, method of making and using |
| 02/18/2004 | CN1138579C Diffusional implantable delivery system |
| 02/18/2004 | CN1138565C Polymer-bound camptothecin derivatives |
| 02/18/2004 | CN1138550C Process of producing extracts of shark |
| 02/18/2004 | CN1138544C Drug composition for treatment and prevention of hepatopathy |
| 02/18/2004 | CN1138543C Lyophilizate of lipid complex of water insoluble camptothecins |
| 02/18/2004 | CN1138542C Method for stabilizing pharmaceutical composition by special use of antioxidant |
| 02/18/2004 | CN1138535C Pharmaceutical compositions contg. effervescent acid -base couple |
| 02/18/2004 | CN1138534C Multiple unit tableted dosage |
| 02/18/2004 | CN1138532C Pharmaceutical aerosol composition |
| 02/18/2004 | CN1138530C Liquid ophthalmic sustained release delivery system |
| 02/18/2004 | CN1138529C Fizzy formulation |
| 02/18/2004 | CN1138528C Peptide/protein suspension temper |
| 02/18/2004 | CN1138505C Anti-angiogenic compositions and method of use |
| 02/17/2004 | USRE38431 Stable liquid formulations of factor viii and factor ix to provide a constant level of the coagulation factor in the blood |
| 02/17/2004 | US6693216 A calcium double salt of organic (preservative) acids of formula ca(r1)(r2) where r1 and r2 are different and are each ooc-r3, r3=saturated or monounsaturated or polyunsaturated c1-c5-alkyl, c1-c5-hydroxyalkyl or phenyl |
| 02/17/2004 | US6693208 Amino acids which deliver active agents to selected biological systems in increased or improved bioavailability |
| 02/17/2004 | US6693167 Peptide-based gemini compounds |
| 02/17/2004 | US6693135 Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| 02/17/2004 | US6693089 Reducing adhesion |
| 02/17/2004 | US6693083 Intracellular drug delivery into an interleukin-2 receptor-bearing cell includes a chemical agent and a copy of an interleukin-2-receptor binding and endocytosis-inducing ligand bound to a water soluble polymer |
| 02/17/2004 | US6693073 Pulmonary delivery of active agents |
| 02/17/2004 | US6692911 Cell delivery compositions |
| 02/17/2004 | US6692773 Treatment of hyperproliferative skin disorders and diseases |
| 02/17/2004 | US6692771 Emulsions as solid dosage forms for oral administration |
| 02/17/2004 | US6692768 Spherical fine particles that are useful in the production of easily-swallowed, controlled-release preparations having a mean particle size of 60-200 mu m |
| 02/17/2004 | US6692767 Solid solution beadlet |
| 02/17/2004 | US6692762 Generating linoleic acid derivatives; obtain chemical intermediates, incubate with lipase, recover fatty acid conjugated to linoleic acid |
| 02/17/2004 | US6692737 In vivo protein production and delivery system for gene therapy |
| 02/17/2004 | US6692734 N,O-amidomalonate platinum complexes |
| 02/17/2004 | US6692733 Composition comprising polymers having a star structure, the polymers, and their use |
| 02/17/2004 | US6692695 Vacuum drying solution or suspension by mixing to boiling without freezing; heat exchanging; monitoring; storage stable viruses and cells |
| 02/17/2004 | US6691770 Cooling apparatus |
| 02/17/2004 | CA2290969C Delayed-release dosage forms of sertraline |
| 02/17/2004 | CA2249299C Combination of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum |
| 02/17/2004 | CA2183755C Pharmaceutical preparation containing plasminogen activators |
| 02/17/2004 | CA2075288C Anthracycline-conjugates |
| 02/17/2004 | CA2074348C Stable compositions for parenteral administration and their use |
| 02/13/2004 | CA2437064A1 Storage-stable, liquid fibrinogen formulation |
| 02/13/2004 | CA2395819A1 Dual-spike release formulation for oral drug delivery |
| 02/12/2004 | WO2004013310A2 Methods of down regulating target gene expression in vivo by introduction of interfering rna |
| 02/12/2004 | WO2004013303A2 Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease |
| 02/12/2004 | WO2004013206A2 Polyamino acids functionalized by at least one hydrophobic group and the therapeutic applications thereof |
| 02/12/2004 | WO2004013182A1 Hyaluronic acid derivatives |
| 02/12/2004 | WO2004013180A2 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| 02/12/2004 | WO2004013165A1 Pegylated t1249 polypeptide |
| 02/12/2004 | WO2004012795A2 Methods of delivering therapeutic agents |
| 02/12/2004 | WO2004012791A2 Improved injection system |
| 02/12/2004 | WO2004012773A1 Polyalkylene glycol acid additives |
| 02/12/2004 | WO2004012772A1 Oral administration of calcitonin |
| 02/12/2004 | WO2004012771A1 Pharmaceutical compositions comprising cyclosporin for oral administration |
| 02/12/2004 | WO2004012770A1 Oral pharmaceutical compositions comprising cyclosporin |
| 02/12/2004 | WO2004012751A1 Bacterial cell wall skeleton component preparaion |
| 02/12/2004 | WO2004012747A1 Air spray for water intake adjustment |
| 02/12/2004 | WO2004012744A1 Use of alkyl phosphocholines in combination with antitumor medicaments |
| 02/12/2004 | WO2004012741A1 Sustained release formulations comprising lamotrigine |